



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,130-H)

PATENT

In the Application of:)
)
Tallman, et al.)
)
Serial No.: 10/045,230)
)
Filed: November 22, 2000)
)
For: Method for Screening GABA-)
Modulatory Compounds for Specified)
Pharmacological Activities)

Art Unit: 1646

Examiner: To be determined

RECEIVED

FEB 06 2003

TECH CENTER 1600/2900

#3
B.G.J
7/2/03

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX IDS
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed Supplemental PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Other Documents

1. Atack, John R. et al., (1999), *Neuropsychopharmacology*, 20(3):255-262.
2. Costa, Erminio et al., (1996), *TiPS*, 17:192-200.
3. Lüddens, Hartmut et al., (1995), *J. psychiat. Res.*, 29(2):77-94.
4. Mohler, H. et al., (1995) *Neurochemical Research*, 20(5):631-636.

The Applicants hereby notify the Examiner of the following commonly owned, co-pending applications that relate to the U.S. Application Serial Nos.:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Attorney Docket No.</u>
09/565,524	May 5, 2000	99,130-A

RECEIVED

FEB 06 2003


TECH CENTER 1600/2900

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Date: January 28, 2003

Respectfully Submitted,

By:


Steven J. Sarussi
Reg. No. 32,784

McDonnell, Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606



FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		99,130-H	10/045,230
		Applicant:	
		Tallman, et al.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date:	Group:
		November 22, 2000	1646

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	1.	Atack, John R. et al., (1999), <i>Neuropsychopharmacology</i> , 20(3):255-262.
	2.	Costa, Erminio et al., (1996), <i>TIPS</i> , 17:192-200.
	3.	Lüddens, Hartmut et al., (1995), <i>J. psychiat. Res.</i> , 29(2):77-94.
	4.	Mohler, H. et al., (1995) <i>Neurochemical Research</i> , 20(5):631-636.
EXAMINER		DATE CONSIDERED

RECEIVED

FEB 16 2003

TECH CENTER 1600/2900

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.